Objective: CYP2B6 variation predicts pharmacokinetic characteristics of its substrates. Consideration for underlying genetic structure is critical to protect against spurious associations with the highly polymorphic CYP2B6 gene.
Introduction
Genetic variation in pathways of drug absorption, delivery, metabolism, and excretion (ADME) contributes to the variability in pharmacokinetic parameters of drug levels and clearance in plasma or cells over time, such as half-life or area under the curve (AUC) [1, 2] . Pharmacokinetic characteristics are often associated with clinical endpoints, such as fasting glucose levels after exposure to antidiabetic medications or viral suppression after exposure to antiretroviral agents [1, 2] . One of the most robust examples of a pharmacokinetic association is observed with genetic variation in the cytochrome p450 2B6 gene (CYP2B6) [1, 2] , whose protein product is an enzyme that metabolizes an array of medications [3] , including bupropion, tamoxifen, propofol, and the nonnucleoside reverse transcriptase inhibitors (NNRTI) efavirenz and nevirapine that are used to treat HIV infection.
Several CYP2B6 loss-of-function alleles are associated with pharmacokinetic characteristics of NNRTIs [4, 5] . Particularly, consistent associations of two single nucleotide polymorphisms (SNPs), rs3475274 and rs28399499, have been observed individually with plasma and intracellular NNRTI levels [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and to a lesser degree with clinical response [10] [11] [12] [13] [14] [15] . The CYP2B6 metabolizer phenotype, derived from the composite genotype for rs3745274 and rs28399499, categorizes individuals as extensive, intermediate, and slow metabolizers of CYP2B6 substrates [16] [17] [18] . The metabolizer phenotype predicts efavirenz [16, 17] and nevirapine [16] plasma concentrations. Regarding clinical response, an association between the metabolizer phenotype and virologic failure, defined as two consecutive HIV viral load measures at least 200 copies/ml, in African-Americans has been suggested [18] .
Confounding by race/ethnicity is a concern in all genetic association studies and the two variants comprising the CYP2B6 metabolizer phenotype may be particularly susceptible to this type of confounding. Substantial differences in minor allele frequencies for these two SNPs occur across racial/ethnic groups [5] [6] [7] [8] and race/ethnicity has often been associated with pharmacokinetic parameters and treatment responses [19] . Gross confounding by race/ ethnicity (population stratification) can be addressed by adjusting statistical models for self-reported ethnicity, but cryptic relatedness and admixture require more detailed genetic ancestry data to guard against false-positive or falsenegative results [20] [21] [22] [23] [24] . Such cryptic relatedness occurs in seemingly homogenous populations within the same selfreported race/ethnicity group [24] . In theory, affected individuals (cases) may be more related to one another than controls and as a result, the allelic distribution among cases may be skewed [24] .
Spurious associations can also occur in a study population that contains individuals from a single ethnic group that has experienced recent genetic admixture [25, 26] . Varying proportions of ancestry from distinct 'parental' populations contribute to a population's genome; admixture describes this mosaic of genetic ancestry. Admixture is particularly evident in African-American and Hispanic-American populations [27] [28] [29] . For example, among African-Americans from different geographical regions in the United States, European ancestry varies between 11.6 and 22.5%; the remaining proportion includes African and Native American ancestry [27] . Thus, addressing population substructure in genetic association studies beyond adjustment for self-reported race/ ethnicity is critical to protect against potentially spurious results.
The Women's Interagency HIV Study (WIHS) is a multiethnic cohort study of HIV-infected and uninfected women who have been followed every 6 months since 1995. We report here the association between genetic variation in CYP2B6 and virologic response to initial antiretroviral therapy regimens containing a NNRTI. Simultaneously, population substructure was characterized using a panel of ancestry informative markers (AIMs) selected to distinguish between European, west African, Asian, and Native American ancestry [30] . CYP2B6 genetic associations were used to demonstrate that residual confounding may exist when underlying genetic structure is ignored.
Participants and methods
The Women's Interagency HIV Study design The WIHS is a prospective cohort study of HIV-infected women and a comparison group of HIV-uninfected women. Participants were recruited from six sites across the United States, located in Bronx/Manhattan, New York; Brooklyn, New York; Washington, DC; Los Angeles, California; San Francisco/Bay Area, California; and Chicago, Illinois. Enrollment was conducted in two phases: 2054 HIV seropositive and 569 seronegative women were enrolled in 1994-1995 and 737 HIV seropositive and 406 seronegative women were enrolled from 2000 to 2001. A more detailed description of the WIHS cohort has been published elsewhere [31, 32] .
Inclusion and exclusion criteria
HIV-infected women who consented to genetic studies, initiated antiretroviral therapy containing a NNRTI during study follow-up, maintained a three-drug HAART regimen at the subsequent visit, had HIV RNA measurements at the visit immediately prior to, the visit of, and the visit immediately after initiating a NNRTI-containing regimen were eligible for this study. Women who were treated with antiretroviral drugs prior to reporting treatment with a NNRTI were excluded to limit the inclusion of women infected with a virus that might have acquired resistance to antiretroviral agents. A total of 100 participants met these study criteria and were genotyped on CYP2B6 SNPs.
Virologic response
HIV viral loads were quantified with an assay with a lower limit of detection of 80 HIV RNA copies/ml. A positive virologic response ('responders') was defined as achievement of an undetectable viral load at the visit during which the NNRTI regimen was first reported or at the visit subsequent to it, which corresponds to a maximum of 54 weeks of treatment. Participants not achieving an undetectable viral load at the visit of first reported NNRTI regimen use (in the previous 6 months) or subsequent visit were classified as 'nonresponders'. This definition conforms to clinical guidelines for treatment with antiretroviral regimens [33] .
SNP selection
CYP2B6 pharmacogenetic association studies in the literature were queried to obtain a list of polymorphisms located in the exons, 3 0 UTR, 5 0 UTR, and splice sites (i.e., putative functional polymorphisms). From this list, SNPs with a minor allele frequency (MAF) of 5% or higher were scored for assay performance on Illumina's GoldenGate genotyping platform (San Diego, California, USA). A total of 11 CYP2B6 SNPs were selected: rs3211370, rs3211397, rs36079186, rs34128717, rs3211374, rs3211371, rs8192709, rs34097093, rs1042389, rs3745274, and rs28399499.
Genotyping and quality control Data for the 11 CYP2B6 SNPs were generated as a subset of a larger genotyping panel (n ¼ 384 SNPs). Four of the 11 CYP2B6 SNP assays (rs3211370, rs3211397, rs36079186, and rs34128717) did not generate three distinct genotypes and were deemed failures. Of the remaining seven SNPs that were successfully genotyped, rs3211374 was monomorphic (no variants observed) in all race/ethnic groups and excluded from the analysis. In total, six CYP2B6 polymorphisms (rs3211371, rs8192709, rs34097093, rs1042389, rs3745274, and rs28399499) passed the quality control criterion of successful genotyping on 89.5% of the samples. Five of the 100 participants genotyped (5%) did not pass the quality control criterion of less than 10% missing genotype data and were excluded from the analysis. Quality control for the entire panel is described in supplementary information, http://links.lww.com/ QAD/A253.
Characterization of genetic ancestry
Selection of ancestry informative markers, genotyping, and quality control. A subset of markers that were originally identified by Smith et al. [30] were utilized to distinguish between west African, European, east Asian, and Native American populations. All participants in the WIHS cohort who consented to genetic studies and had DNA available were characterized for genetic ancestry as these markers are being used for all genetic association studies being conducted in the WIHS. A total of 185 AIMs were selected as part of a larger panel (n ¼ 384); 168 (91%) AIMs passed the quality control criterion of successful genotyping on 89.5% of the samples. Four of 100 eligible participants did not pass the quality control criterion of less than 10% missing genotype data and were excluded from the analysis. Quality control for the entire panel is described in supplementary information, http:// links.lww.com/QAD/A253.
Estimation of genetic ancestry components. Individual genetic ancestry proportions for 2318 WIHS women were inferred using the software package STRUCTURE 2.3.1 [22, 34] , which employs a Bayesian Markov chain Monte Carlo clustering algorithm. A 30 000 repetition burn-in period and 10 000 subsequent iterations for different values of k (number of assumed subpopulations, k ¼ 3-6) were initiated under the admixture model with independent allele frequencies. Four independent simulations for each value of k were performed to ensure that estimates were consistent across runs. The admixture model with the greatest log likelihood for each value of k was selected. HapMap2 and HapMap3 [35] reference population data on 168 AIMs and 105 AIMs, respectively, were included in the STRUCTURE analyses to increase the accuracy of admixture estimation [36] . Results were formatted and graphically displayed using the Distruct 1.1 software package [37] .
Genetic ancestry components were also evaluated with principal components analysis on the WIHS genotype data for 168 AIMs (n ¼ 2318) following the method used with the EIGENSTRAT software [38, 39] . Adjusting for principal components is the preferred method to control for population substructure, as the model does not depend on an assumption of the number of source populations [38, 39] . Principal components were used in the models examining the association between CYP2B6 genotypes and virologic response to therapy.
Statistical analysis
The final dataset consisted of 91 participants meeting study inclusion and exclusion criteria and with complete data for CYP2B6 and AIM SNPs. Logistic regression was used to test associations between each CYP2B6 polymorphism and virologic response. Odds ratios (ORs) per allele and 95% confidence intervals (CIs) were estimated by modeling the genotypes as an ordinal variable, wherein common allele homozygotes, heterozygotes, and minor allele homozygotes were coded as 0, 1, and 2, respectively. This log-additive model provides a P value for corresponding test of the trend for increased probability of virologic response per allele.
CYP2B6 metabolizer phenotypes were constructed using two polymorphisms, rs3745274 and rs28399499, to test the association between the metabolizer phenotype and virologic response. Women who were common allele homozygotes at rs3745274 and rs28399499 (GG and TT, respectively) were coded as 0 'extensive metabolizers'. Women with one heterozygote genotype and one common allele homozygote genotype at either polymorphism were coded as 1 'intermediate metabolizers'. Women with a total of two minor alleles (one minor allele homozygote genotype, or two heterozygote genotypes) across both SNPs were coded as 2 'slow metabolizers'. No women carried one minor allele at one SNP and two minor alleles at the other SNP, or four minor alleles across the two SNPs.
Metabolizer phenotype-specific ORs and 95% CIs for intermediate metabolizers and slow metabolizers compared with extensive metabolizers, were estimated with exact logistic regression, as there were zero nonresponders with the slow metabolizer phenotype. Additionally, the metabolizer phenotype was treated as an ordinal variable to obtain the exact P for trend. Nominal P values are reported throughout the study.
To assess the potential confounding effects of population substructure, models were fit unadjusted, adjusted for self-reported race/ethnicity (non-Hispanic White, African-American, Hispanic, and Asian/other), and adjusted for genetic ancestry principal components. The three most important principal components that accounted for the largest change in the main effect b in the individual SNP analyses were included in the metabolizer phenotype model. Self-reported adherence was also evaluated as a potential confounder (change in the genotype main effect b of 10% or more was considered confounding). Adherence data were taken at the visit at which the participant achieved the virologic response outcome as the adherence variable at this visit reflects treatment adherence in the 6 months leading up to the visit in which the outcome was achieved. For modeling purposes, adherence was dichotomized as at least 95% adherent and less than 95% adherent from original categories as collected (100, 95-99, 75-95, <75%).
Results
Detection of population substructure Figure 1 illustrates the individual ancestry proportions for 2318 WIHS participants (n ¼ 1796 HIV seropositive and n ¼ 522 seronegative) by self-reported ethnic groups for k ¼ 4 cluster STRUCTURE models (results for self-reported Asian, Native American, and 'other' groups are not illustrated because of small numbers). In summary, the WIHS women likely descended from four source populations: European, Asian, Yoruban, and 2100 AIDS 2012, Vol 26 No 16 non-Yoruban African ancestry. Admixture was estimated by including reference population data from HapMap2 (Fig. 1a) and HapMap3 (Fig. 1b) . Assuming k ¼ 4 subpopulations (log likelihood ¼ À449 517.3), the fourth subpopulation (yellow) was represented in WIHS African-American and Hispanic women, but was not substantially present in Yoruban, European, or east Asian reference populations (Fig. 1a) . The k ¼ 4 model suggests that there is ancestry in the WIHS that is not represented in the HapMap2 populations. Assuming k ¼ 4 subpopulations (log likelihood ¼ À358 970.2) with HapMap3 data, the fourth subpopulation (orange) was overrepresented in the Maasai Kenyans, in whom the average proportion of ancestry attributed to the fourth subpopulation was 79% (Fig. 1b) . As the Maasai population show admixture with Yoruban ancestry (12%), the fourth component was labeled as non-Yoruban African ancestry. The HapMap3 Mexican-American population shows a considerable amount of admixture represented by the Asian subpopulation, which was inferred to represent Native American ancestry as native American ancestry is correlated with east Asian ancestry [40] .
The estimated admixture proportions in self-reported African-American, Hispanic, and non-Hispanic White women were evaluated by the geographic location of the WIHS sites (results not shown). In contrast to African-Americans and Whites, ancestry proportions in Hispanics varied across sites. There was a gradient of decreasing European ancestry and increasing Asian ancestry in Hispanics from east to west. Additionally, African admixture (Yoruban and non-Yoruban) was substantial in Hispanics in New York (0.13-0.19) but minimal among Los Angeles Hispanics (0.03-0.04).
Although estimating ancestry proportions using STRUCTURE is beneficial to labeling subpopulations for ease of interpretation, principal components are preferred as ancestry covariates in statistical models. Graphical display of the principal components illustrates the separation of broad ethnic groups and the dispersion of individuals along the axes confirms the variation that exists within self-reported ethnic groups as seen in Fig. 1 . CYP2B6 associations with response to nonnucleoside reverse transcriptase inhibitors and the impact of population substructure Nine out of 21 virologic nonresponders (43%) had a nadir CD4 þ cell count lower than 200 cells/ml prior to reporting a NNRTI-based regimen, a difference that was not statistically significantly different from responders (N ¼ 24/70, 34%, P ¼ 0.47). The median viral load measured at the visit prior to first report of a NNRTI was 28 000 copies/ml [interquartile range (IQR) 6300-110 000] for responders and 45 000 copies/ml (IQR 13 000-69 000) for nonresponders (Kruskal-Wallis test, P ¼ 0.57). Nearly all of the nonresponders (n ¼ 18/21) reported having African-American race/ethnicity and the remaining three women reported having Hispanic race/ethnicity. Among the responders (N ¼ 70) , 53% selfreported as African-American, 31% as White, and 7% as Hispanic.
The genotype frequencies by responder status and MAF by self-reported ethnicity are given in Table 1 for the six SNPs that were successfully genotyped. There were no nonresponders among carriers of the minor allele for rs3211371 and, therefore, effect estimates could not be calculated. The six SNPs were not in linkage disequilibrium (r 2 ! 0.80) in any of the WIHS self-reported racial/ethnic groups ( Supplementary Figure 1 , http:// links.lww.com/QAD/A253).
The associations between the remaining five SNPs (rs3409703, rs1042389, rs8192709, rs3745274, and rs28399499) and response to a NNRTI-based regimen are shown in Table 2 . Overall, no statistically significant associations between these five SNPs and virologic response were observed after adjustment for self-reported race/ethnicity (second column). However, a high magnitude of effect on virologic response was observed for the two SNPs which comprise the metabolizer phenotype (rs3745274 and rs28399499) after adjustment for genetic ancestry principal components and the effect of rs3745274 reached statistical significance (P trend ¼ 0.03).
When considering the joint effects of the two SNPs, intermediate and slow metabolizers were 2.90 (95% CI 0.79-12.28) and 13.44 (95% CI 1.66 to infinity) times as likely to respond to NNRTIs compared to extensive metabolizers after adjustment for genetic ancestry principal components (P trend ¼ 0.005; Table 3 ). Substantial evidence of confounding is present with the metabolizer phenotype when comparing the crude, self-reported race/ethnicity-adjusted and genetic ancestry principal component-adjusted estimates. After adjustment for self-reported race/ethnicity, the OR for slow metabolizers compared to extensive metabolizers increased by 54%. After adjustment for genetic 2102 AIDS 2012, Vol 26 No 16 
Discussion
We observed a statistically significant association between the CYP2B6 metabolizer phenotype (joint effect of rs3745274 and rs28399499) and virologic response to NNRTI-based antiretroviral regimens (P trend ¼ 0.005). This association was strongly confounded by underlying population substructure for which adjustment of selfreported race/ethnicity was not a sufficient control. Our findings confirm prior report of the role of these SNPs in NNRTI metabolism and further highlight the importance of controlling for population substructure using genetic ancestry estimates, such as principal components, in genetic association studies.
It is possible that both genetic ancestry estimates and selfreported race/ethnicity may confound the association CYP2B6 variation and response to NNRTIs Frasco et al. 2103 between SNPs and outcome, as would be seen if the additional factors captured by self-reported ethnic group (e.g., socio-economic status) are also associated with the SNP of interest. However, adjusting for both principal components and self-reported race/ethnicity did not change the estimated effect of CYP2B6 metabolizer phenotype on virologic response to NNRTIs compared to principal components alone. These findings suggest that principal components alone capture the underlying population substructure and the additional factors related to self-identification in a particular ethnic group are not associated with these SNPs.
To our knowledge, we are the first to report a statistically significant joint effect of rs3745274 and rs28399499 (metabolizer phenotype) on virologic response to NNRTIs in a multiethnic observational study of HIVinfected women. Previously, a study of participants randomized to efavirenz in the AIDS Clinical Trial Group (ACTG), of which 19% were women and 34% were African-American, explored the effect of the metabolizer phenotype on virologic failure [18] . The incidence of virologic failure adjusted for the competing event of efavirenz discontinuation was lower among self-reported African-American participants with the slow metabolizer phenotype (P ¼ 0.02) [18] . However, this effect was not seen in whites or Hispanics, which is likely an artifact of the lower allele distribution in non-African-Americans. The authors reported that the results were similar after incorporation of genome-wide association study (GWAS) principal components, although it is unclear whether this model was tested in all participants.
The two polymorphisms that contribute to the CYP2B6 metabolizer phenotype are functionally relevant. The minor allele (T) at rs3745274 causes an aberrant splicing mechanism that decreases expression and activity of CYP2B6 in the liver [41] . The minor allele (C) at rs28399499 has been consistently associated with reduced CYP2B6 expression [1, 7] , although the mechanism is unclear [41] . Additionally, it is well established that both SNPs predict several short-term NNRTI pharmacokinetic parameters, such as AUC, oral clearance, and half-life [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 42] . In a separate WIHS study, carriers of the TT genotype compared to GG and GT genotypes at rs3745274 experienced an over three-fold increase (P ¼ 1.0 Â 10 -10 ) in efavirenz concentration in hair specimens after adjustment for nongenetic predictors of long-term efavirenz exposure (e.g. adherence and consumption of orange juice) [39] . The minor allele C at rs28399499 was associated with a 1.70-fold increase of efavirenz levels in hair (P ¼ 0.02) [43] . The independent association of these SNPs with long-term exposure to efavirenz lends support to our results of increased probability of virologic suppression in intermediate and slow metabolizers through the mechanism of sustained increased drug levels.
A limitation of this study is the absence of viral genotyping on pre-NNRTI specimens from each participant, which would allow us to limit exclusion of treatmentexperienced NNRTI users to those who are resistant to NNRTIs. There is no reason to believe that the exclusion of treatment-experienced women who reported initial treatment with an NNRTI would bias the results away from the null. Another limitation of our study is the small sample size; however, we observed a robust and statistically significant association that survived a Bonferroni correction for the number of tests we performed (corrected a ¼ 0.05/6 ¼ 0.008). The functional role of the SNPs comprising the metabolizer phenotype and associations within and external to the WIHS with pharmacokinetic parameters is compelling enough to assign a high prior probability that this association is real.
Although patients with CYP2B6 intermediate and slow metabolizer phenotypes are more likely to achieve undetectable viral loads after treatment with NNRTIs in our study, it is possible that the low grade toxicities that are experienced in carriers of the minor allele at rs3745274 [4, 9] could impact adherence to NNRTIs over time or result in drug-switching. This is an area of active research in the WIHS. Nevertheless, the association of the CYP2B6 metabolizer phenotype and response to NNRTIs has important potential for clinical decision-making, in which the genetic profile of an individual is taken into account prior to the initiation of a given antiretroviral agent. In fact, this paradigm has already been implemented with the antiretroviral agent, abacavir, in which acquisition of genetic information is highly recommended prior to the institution of this drug, in order to avoid potential hypersensitivity reactions [44] . The body of evidence supporting a role for CYP2B6 SNPs in NNRTI virologic response suggests that further study is warranted to determine whether this information can be used in clinical decision-making related to antiretroviral regimens.
